GABA_A receptor autoimmunity after alemtuzumab treatment for multiple sclerosis

Giorgia Teresa Maniscalco¹, Sara Mariotto², Romana Höftberger¹+10

• ¹From the Department of Neurology and Stroke Unit "A. Cardarelli Hospital" (G.T.M., G.S., V.M., M.N., P.C., C.F.); Multiple Sclerosis Centre "A. Cardarelli Hospital" (G.T.M., C.F.), Naples; Neurology Unit (S.M., S.F., S.B.), Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy; Institute of Neurology (R.H.), Medical University of Vienna, Austria; Multiple Sclerosis Center (R.C.), ASST - Spedali Civili of Brescia, Montichiari; Department of Neuroradiology (S.G.), San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan; and Ragon Institute of Massachusetts General Hospital (M.S.), Massachusetts Institute of Technology and Harvard Medical School, Cambridge.+1